Periodontal Disease : Chronic PeriodontitisPAROPAMNCT02793453
Antimicrobial Peptides in Periodontitis
A study testing periodontal smears in people with Periodontal Disease : Chronic Periodontitis, run by CHU de Reims at 1 site in France.
Trial summary
Periodontal diseases are complex chronic pathologies presenting a high prevalence worldwide. Etiopathological process involved in initiation and progression of these multifactorial diseases are not well understood, explaining the huge clinical forms variability and the complexity of the currently used classification… Read more about this study
- Who is it for?
- Ages 35 to 65 years
- Conditions the study is for
- Periodontal Disease : Chronic Periodontitis
- What is being tested?
- periodontal smears
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 29 participants
- Where
- 1 siteFrance
- Study dates
- 19 Jan 2016to Apr 2016
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients suffering of moderate to severe chronic periodontitis as described by the classification Armitage-1999, aged 35-65yo
Who cannot join
- Pregnant females, patients suffered from any other systemic diseases (cardiovascular, pulmonary, liver, cerebral, diseases or diabetes, cancer)
- patients that had received antibiotic treatment in the previous 3 months or who were taking long-term anti-inflammatory drugs; who had received a course of periodontal treatment or orthodontics treatment within the last 6 months; who were heavy smokers (>5 cig/day)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Antimicrobial Peptides in Periodontitis : a Pilot Study
Periodontal diseases are complex chronic pathologies presenting a high prevalence worldwide. Etiopathological process involved in initiation and progression of these multifactorial diseases are not well understood, explaining the huge clinical forms variability and the complexity of the currently used classification of periodontal diseases. Recently, the implication of antimicrobial peptides (AMPs) have been suggested as potential track of explanation for periodontal diseases pathogeny. The here presented study explore the level of expression of genes coding those peptides by studying periodontal smears obtained from healthy and periodontitis patients.
Read the detailed description
This study explore the level of expression of genes coding those peptides by studying Messenger RNA (mRNA) purified from periodontal smears obtained from healthy and periodontitis patients by "Masterpure©" protocol.After reverse transcription (RT-PCR), in-silico design of primers and specificity and efficiency calculation, Complementary DNA (cDNA) are quantified by a semi-quantitative method (delta-delta CT) vs a Housekeeping gene. Wilcoxon-Mann \& Whitney tests and Chi² tests are performed to check the significativity of the results between groups.
- Being tested
- periodontal smears
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
periodontal smearsOther
| Study group | Role | What they receive |
|---|---|---|
| Diseased | Other | Patients suffering of moderate to severe chronic periodontitis Receives: Other: periodontal smears |
| Healthy | Other | Healthy Patients not suffering of any periodontal disease a Receives: Other: periodontal smears |
What is being measured
The primary outcome is the main question the study is designed to answer.
Antimicrobial peptides expression levels
Level of expression of antimicrobial peptides assessed by RT-PCR
Measured: Day 0
Secondary outcomes (1)
mRNA quantity
Quantity of mRNA purified on the smears
Measured: Day 0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2016 (estimated)
- Study start19 Jan 2016
- Primary completion23 Mar 2016
- Study completionApr 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Periodontal Disease : Chronic PeriodontitisStudies of the same condition, open and under way.
- More trials run by CHU de ReimsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 29 participants (actual)
Sponsor and investigators
- Lead sponsor
- CHU de Reims
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02793453
- Sponsor's protocol ID
- PO15100
- Acronym
- PAROPAM
- Status last verified
- Mar 2017
- First submitted
- 27 May 2016
- Last updated
- 21 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
Publications
Jourdain ML, Pierrard L, Kanagaratnam L, Velard F, Sergheraert J, Lefevre B, Gangloff SC, Braux J. Antimicrobial peptide gene expression in periodontitis patients: A pilot study. J Clin Periodontol. 2018 May;45(5):524-537. doi: 10.1111/jcpe.12879. Epub 2018 Mar 23.
PubMed 29446150
Study at a glance
From the registry record, last updated by the sponsor on 21 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Antimicrobial Peptides in Periodontitis : a Pilot Study
- ClinicalTrials.gov ID
- NCT02793453
- Acronym / sponsor ID
- PAROPAM / PO15100
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 29 participants (actual)
- Lead sponsor
- CHU de ReimsUniversity, hospital or other
- Study start
- 19 Jan 2016 (actual)
- Primary completion
- 23 Mar 2016 (actual)
- Study completion
- Apr 2016 (actual)
- First posted
- 8 Jun 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Periodontal diseases are complex chronic pathologies presenting a high prevalence worldwide. Etiopathological process involved in initiation and progression of these multifactorial diseases are not well understood, explaining the huge clinical forms variability and the complexity of the currently used classification of periodontal diseases. Recently, the implication of antimicrobial peptides (AMPs) have been suggested as potential track of explanation for periodontal diseases pathogeny. The here presented study explore the level of expression of genes coding those peptides by studying periodontal smears obtained from healthy and periodontitis patients.
Detailed description
This study explore the level of expression of genes coding those peptides by studying Messenger RNA (mRNA) purified from periodontal smears obtained from healthy and periodontitis patients by "Masterpure©" protocol.After reverse transcription (RT-PCR), in-silico design of primers and specificity and efficiency calculation, Complementary DNA (cDNA) are quantified by a semi-quantitative method (delta-delta CT) vs a Housekeeping gene. Wilcoxon-Mann \& Whitney tests and Chi² tests are performed to check the significativity of the results between groups.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Diseased | Other | Other: periodontal smearsPatients suffering of moderate to severe chronic periodontitis |
| Healthy | Other | Other: periodontal smearsHealthy Patients not suffering of any periodontal disease a |
Who may qualify
- Ages
- 35 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients suffering of moderate to severe chronic periodontitis as described by the classification Armitage-1999, aged 35-65yo
Key exclusion criteria (2 listed)
- Pregnant females, patients suffered from any other systemic diseases (cardiovascular, pulmonary, liver, cerebral, diseases or diabetes, cancer)
- patients that had received antibiotic treatment in the previous 3 months or who were taking long-term anti-inflammatory drugs; who had received a course of periodontal treatment or orthodontics treatment within the last 6 months; who were heavy smokers (>5 cig/day)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| periodontal smears | Other | Diseased, Healthy |
Primary outcome
Antimicrobial peptides expression levels
Time frame: Day 0
Level of expression of antimicrobial peptides assessed by RT-PCR
1 secondary outcome
mRNA quantity
Time frame: Day 0
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Jan 2026.
- Background: PubMed 29446150Jourdain ML, Pierrard L, Kanagaratnam L, Velard F, Sergheraert J, Lefevre B, Gangloff SC, Braux J. Antimicrobial peptide gene expression in periodontitis patients: A pilot study. J Clin Periodontol. 2018 May;45(5):524-537. doi: 10.1111/jcpe.12879. Epub 2018 Mar 23.
Related trials for Periodontal Disease : Chronic Periodontitis
RecruitingObservational study
Prevalence and Associated Factors of High BMI and Periodontitis in Thai Adults Aged Under 60 Years
Diabete Mellitus, Dyslipidaemia
RecruitingObservational study
Evaluation of Masticatory Performance in Patients With Periodontitis
Periodontitis, Adult, Periodontitis
Not yet recruitingObservational study
Evaluation of Changes in Oral Health-related Quality of Life During the Treatment of Periodontitis.
Periodontitis, Adult, Periodontitis
Recruiting
Postoperative Pain and Success of Single-Visit Root Canal Treatment Using Different Root Canal Sealers in Asymptomatic Teeth
Single-visit, Periapical Periodontitis
Active, not recruiting
Utilization of a Videoscope in Periodontal Regeneration
Chronic Periodontitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing periodontal smears in people with Periodontal Disease : Chronic Periodontitis, run by CHU de Reims at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Antimicrobial peptides expression levels (time frame: Day 0). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02793453, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Jan 2026.